AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2021
Jun 21, 2021
31801_dirs_2021-06-21_6c7c3910-c26e-458e-9490-25bef8ad6b5a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-06-17
Reporting Person: MARINO JAMES J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-17 | Non-Qualified Stock Option (right to buy) | $28.00 | A | 12000 | Acquired | 2031-06-17 | Common Stock (12000) | Direct |
Footnotes
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Prospectus
2026
Apr 2
Regulatory Filings
2026
Apr 2
Prospectus
2026
Apr 1
Major Shareholding Notification
2026
Mar 26